Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johanna Wassermann

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
World Journal of Hepatology|September 19, 2015
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingMohamed Bouattour, Audrey Payancé, Johanna Wassermann
Expert Opinion on Drug Safety|December 2, 2022
Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinibJohanna Wassermann, Corinne Isnard Bagnis, Laurence Leenhardt, et al.
Presse Medicale (Paris, France : 1983)|September 21, 2013
[Vitamin D and cancers]Marc Espié, Johanna Wassermann, Elisabeth de Kermadec, et al.
Bulletin Du Cancer|June 19, 2024
[Adherence to endocrine therapy: A major issue in breast cancer management]Florence Coussy, Marie Robert, Cristian Villanueva, et al.
Endocrine-Related Cancer|March 20, 2020
Redifferentiation of radioiodine-refractory thyroid cancersCamille Buffet, Johanna Wassermann, Fabio Hecht, et al.
Cardiovascular Research|January 31, 2019
Cardiac arrhythmia considerations of hormone cancer therapiesMary Barber, Lee S Nguyen, Johanna Wassermann, et al.
The Oncologist|March 22, 2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenibMaxime Ronot, Mohamed Bouattour, Johanna Wassermann, et al.
The Oncologist|December 18, 2015
Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid CarcinomasJohanna Wassermann, Marie-Odile Bernier, Jean-Philippe Spano, et al.
European Thyroid Journal|January 18, 2024
Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancersHelene Theodon, Erell Guillerm, Johanna Wassermann, et al.
Breast (Edinburgh, Scotland)|March 9, 2025
Awareness of genomic testing among patients with breast cancer in EuropeAntonella Cardone, Dany Bell, Conchi Biurrun, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
World Journal of Hepatology|September 19, 2015
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingMohamed Bouattour, Audrey Payancé, Johanna Wassermann
Expert Opinion on Drug Safety|December 2, 2022
Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinibJohanna Wassermann, Corinne Isnard Bagnis, Laurence Leenhardt, et al.
Presse Medicale (Paris, France : 1983)|September 21, 2013
[Vitamin D and cancers]Marc Espié, Johanna Wassermann, Elisabeth de Kermadec, et al.
Bulletin Du Cancer|June 19, 2024
[Adherence to endocrine therapy: A major issue in breast cancer management]Florence Coussy, Marie Robert, Cristian Villanueva, et al.
Endocrine-Related Cancer|March 20, 2020
Redifferentiation of radioiodine-refractory thyroid cancersCamille Buffet, Johanna Wassermann, Fabio Hecht, et al.
Cardiovascular Research|January 31, 2019
Cardiac arrhythmia considerations of hormone cancer therapiesMary Barber, Lee S Nguyen, Johanna Wassermann, et al.
The Oncologist|March 22, 2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenibMaxime Ronot, Mohamed Bouattour, Johanna Wassermann, et al.
The Oncologist|December 18, 2015
Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid CarcinomasJohanna Wassermann, Marie-Odile Bernier, Jean-Philippe Spano, et al.
European Thyroid Journal|January 18, 2024
Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancersHelene Theodon, Erell Guillerm, Johanna Wassermann, et al.
Breast (Edinburgh, Scotland)|March 9, 2025
Awareness of genomic testing among patients with breast cancer in EuropeAntonella Cardone, Dany Bell, Conchi Biurrun, et al.
Pageof 3